PROCTER & GAMBLE HEALTH | MARKSANS PHARMA. | PROCTER & GAMBLE HEALTH/ MARKSANS PHARMA. |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.6 | 24.4 | 141.9% | View Chart |
P/BV | x | 10.6 | 4.5 | 236.0% | View Chart |
Dividend Yield | % | 2.0 | 0.3 | 692.5% |
PROCTER & GAMBLE HEALTH MARKSANS PHARMA. |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
MARKSANS PHARMA. Mar-23 |
PROCTER & GAMBLE HEALTH/ MARKSANS PHARMA. |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 74 | 7,209.9% | |
Low | Rs | 3,883 | 39 | 10,033.6% | |
Sales per share (Unadj.) | Rs | 740.7 | 40.9 | 1,812.3% | |
Earnings per share (Unadj.) | Rs | 138.2 | 5.9 | 2,361.0% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 7.0 | 2,216.9% | |
Dividends per share (Unadj.) | Rs | 95.00 | 0.50 | 19,000.0% | |
Avg Dividend yield | % | 2.1 | 0.9 | 232.4% | |
Book value per share (Unadj.) | Rs | 447.6 | 38.5 | 1,162.3% | |
Shares outstanding (eoy) | m | 16.60 | 453.16 | 3.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 1.4 | 451.1% | |
Avg P/E ratio | x | 33.5 | 9.7 | 346.3% | |
P/CF ratio (eoy) | x | 29.8 | 8.1 | 368.8% | |
Price / Book Value ratio | x | 10.3 | 1.5 | 703.4% | |
Dividend payout | % | 68.7 | 8.5 | 804.7% | |
Avg Mkt Cap | Rs m | 76,761 | 25,631 | 299.5% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 2,394 | 86.1% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 18,521 | 66.4% | |
Other income | Rs m | 184 | 593 | 31.0% | |
Total revenues | Rs m | 12,480 | 19,115 | 65.3% | |
Gross profit | Rs m | 3,247 | 3,393 | 95.7% | |
Depreciation | Rs m | 281 | 519 | 54.2% | |
Interest | Rs m | 8 | 91 | 8.4% | |
Profit before tax | Rs m | 3,142 | 3,377 | 93.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 723 | 117.1% | |
Profit after tax | Rs m | 2,295 | 2,653 | 86.5% | |
Gross profit margin | % | 26.4 | 18.3 | 144.1% | |
Effective tax rate | % | 27.0 | 21.4 | 125.9% | |
Net profit margin | % | 18.7 | 14.3 | 130.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 16,997 | 68.9% | |
Current liabilities | Rs m | 6,791 | 3,654 | 185.9% | |
Net working cap to sales | % | 40.0 | 72.0 | 55.6% | |
Current ratio | x | 1.7 | 4.7 | 37.1% | |
Inventory Days | Days | 263 | 6 | 4,607.9% | |
Debtors Days | Days | 343 | 82 | 418.1% | |
Net fixed assets | Rs m | 10,617 | 5,246 | 202.4% | |
Share capital | Rs m | 166 | 453 | 36.6% | |
"Free" reserves | Rs m | 7,265 | 16,998 | 42.7% | |
Net worth | Rs m | 7,431 | 17,452 | 42.6% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 22,330 | 22,242 | 100.4% | |
Interest coverage | x | 409.1 | 38.0 | 1,076.7% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.6 | 0.8 | 66.1% | |
Return on assets | % | 10.3 | 12.3 | 83.6% | |
Return on equity | % | 30.9 | 15.2 | 203.1% | |
Return on capital | % | 42.4 | 19.9 | 213.3% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 13.1 | 7.3 | 179.3% | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 1,605 | 1,348 | 119.1% | |
Fx inflow | Rs m | 1,465 | 6,491 | 22.6% | |
Fx outflow | Rs m | 1,605 | 1,348 | 119.1% | |
Net fx | Rs m | -140 | 5,143 | -2.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 2,374 | 99.4% | |
From Investments | Rs m | -215 | -2,592 | 8.3% | |
From Financial Activity | Rs m | -985 | 1,978 | -49.8% | |
Net Cashflow | Rs m | 1,160 | 1,760 | 65.9% |
Indian Promoters | % | 0.0 | 43.9 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 20.7 | 96.3% | |
FIIs | % | 6.2 | 15.6 | 40.1% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 56.2 | 85.8% | |
Shareholders | 56,778 | 254,699 | 22.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | MARKSANS PHARMA. | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.43% | 3.18% | 0.45% |
1-Month | -1.15% | 19.46% | 2.55% |
1-Year | 0.73% | 110.18% | 56.14% |
3-Year CAGR | -8.76% | 36.10% | 15.22% |
5-Year CAGR | 4.97% | 48.06% | 19.63% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the MARKSANS PHARMA. share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of MARKSANS PHARMA. the stake stands at 43.9%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of MARKSANS PHARMA..
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
MARKSANS PHARMA. paid Rs 0.5, and its dividend payout ratio stood at 8.5%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of MARKSANS PHARMA..
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.